You are here

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

-- Ended 2018 with a cash position of $449.0 million ---- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 trial of M254 in immune thrombocytopenia (ITP) --
Friday, February 22, 2019 - 06:30